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AbSTrACT
Question Anxiety disorders are the most prevalent 
childhood mental disorders. They also start early and 
persist, causing high individual and collective costs. To 
inform policy and practice, we therefore asked: What is 
the best available research evidence on preventing and 
treating these disorders?
Methods We sought randomised controlled trials 
(RCTs) evaluating interventions addressing anxiety 
problems in young people. We identified RCTs by 
searching CINAHL, ERIC, MEDLINE, PsycINFO and Web 
of Science. Thirty-three RCTs met inclusion criteria—
evaluating 8 prevention programmes, 12 psychosocial 
treatments and 7 pharmacological treatments. We then 
conducted meta-analyses by intervention type.
Findings For prevention, the cognitive-behavioural 
therapy (CBT) programme Coping and Promoting 
Strength stood out for reducing anxiety diagnoses. For 
psychosocial treatment, 9 CBT interventions also reduced 
diagnoses: Cool Kids; Cool Little Kids Plus Social Skills; 
Coping Cat; Coping Koala; One-Session Treatment; 
Parent Education Program; Skills for Academic and Social 
Success; Strongest Families and Timid to Tiger. Successful 
CBT interventions were used with children ranging from 
pre-schoolers to teens in homes, communities/schools 
and clinics. For pharmacological treatment, selective-
serotonergic-reuptake-inhibitors (SSRIs) significantly 
improved symptoms. Fluoxetine stood out for also 
reducing post-test diagnoses, but caused adverse events. 
Meta-analyses indicated strongest effects for CBT (Log 
OR=0.95; 95% CI, 0.69 to 1.21) and SSRI treatments 
(1.57; 1.09 to 2.06).
Conclusions CBT is effective for preventing and 
treating childhood anxiety—across a range of ages and 
formats. Fluoxetine is also an effective treatment but side 
effects must be managed. CBT prevention and treatment 
interventions should be made widely available, adding 
fluoxetine in severe cases.
bACkground
Anxiety disorders are characterised by excessive 
fear and behavioural disturbances that cause clini-
cally significant distress and/or impairment in func-
tioning.1 These disorders include: separation anxiety 
disorder; selective mutism; specific phobias; social 
anxiety disorder; panic disorder; agoraphobia and 
generalised anxiety disorder.1 With overall preva-
lence estimated at 6.5%, anxiety disorders are the 
most common childhood mental disorders, making 
them a crucial public health concern.2 3 Because these 
disorders typically start early and persist, they also 
cause distress and impairment across the lifespan,4 
making them a leading cause of disability worldwide.5 
Beyond the costs for children and families,6 anxiety 
disorders also lead to collective burdens. Considering 
direct and indirect healthcare and related expen-
ditures, these disorders are estimated to cost up to 
€1200 (US$1300) per person annually—or €83.2B in 
total for Europe annually (2019 equivalency).7
Given these high burdens, prevention should 
be a priority. However, prevention investments 
are meagre, even in high-income jurisdictions. For 
example, in the UK and Canada, less than 6% of 
health spending goes towards public health including 
prevention, with even less allocated for preventing 
childhood mental disorders such as anxiety.8–10 Exac-
erbating this situation, access to psychosocial treat-
ments for childhood anxiety is also limited in most 
jurisdictions.2 11 In contrast, psychiatric prescribing 
for these disorders is rising. For example, in Europe 
and the USA,  paediatric prescriptions for antidepres-
sants, commonly used to treat anxiety disorders,12 
showed increases ranging from 18% to 61% between 
2005 and 2012.13
To address these shortfalls and imbalances, poli-
cymakers need robust research evidence on effective 
interventions across the prevention-through-treat-
ment spectrum to inform public priorities. Prac-
titioners also need this information to guide the 
implementation of effective approaches.
objeCTiveS
To inform policy and practice, we asked: What is the 
best available research evidence on preventing and 
treating childhood anxiety disorders? To provide 
comprehensive data, we included prevention 
programmes, psychosocial treatments and pharmaco-
logical treatments. To our knowledge, this is the first 
systematic review and meta-analysis covering this full 
intervention continuum for childhood anxiety. Past 
reviews/meta-analyses have examined only preven-
tion14–16 or only treatment.17–21 This review also 
includes recent studies not covered in prior reviews.
MeThodS
We searched CINAHL, ERIC, MEDLINE and 
PsycINFO databases using the terms: anxiety 
disorder, anxiety, agoraphobia, generalised anxiety 
disorder, panic disorder, phobic disorder, separa-
tion anxiety disorder, specific phobia, social anxiety 
disorder, social phobia, OR selective mutism AND 
prevention, intervention OR treatment. Our search 
dates were January 1950 through May 2018. We 
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applied limiters, seeking only randomised controlled trials (RCTs) 
that evaluated interventions addressing anxiety in individuals aged 
18 years or younger. We also limited our searches to English-lan-
guage articles due to most research being published in this language 
and due to translation capacity not being available within the team. 
We then searched Evidence-Based Mental Health and the Cochrane 
and Campbell Collaboration databases to identify relevant system-
atic reviews that we subsequently hand-searched. After title 
screening, 2 authors independently assessed all relevant abstracts. 
Relevant studies were then retrieved and independently assessed by 
2 authors who identified those that met all inclusion criteria (see 
table 1). We next identified supplemental publications for accepted 
RCTs in Web of Science using intervention and author names and 
article titles. Figure 1 shows our search process.22
We limited our review to RCTs because this design is the most 
rigorous way of evaluating interventions. We applied additional 
quality indicators including requiring reliable and valid measures. 
To minimise risk of bias, after title screening at least 2 authors inde-
pendently completed each step of the review process, resolving 
disagreements by consensus. To maximise policy and practice 
applicability, we also focused on studies in high-income countries 
because most low-income countries have yet to mobilise children’s 
mental health services on a large scale.23 This approach yielded 
33 RCTs meeting all inclusion criteria—reporting on 8 prevention 
programmes, 12 psychosocial treatments and 7 pharmacothera-
pies. We then assessed risk-of-bias for each RCT using the Cochrane 
tool, based on data provided in the RCTs; this tool assesses biases 
across 5 domains which can lead to inaccurate estimates of inter-
vention effects.24 25 We augmented this process by also assessing 
conflicts of interest.
For all interventions, we extracted diagnostic findings for all 
follow-ups and symptom findings for longest follow-ups. We 
also identified common adverse events, where reported. We then 
conducted random-effects meta-analyses. Due to heterogeneity 
regarding participants, interventions, comparators and outcome 
measures across the 3 intervention groups, we conducted separate 
meta-analyses for: 1) diagnoses prevented for cognitive-behavioural 
therapy (CBT) prevention programmes versus comparison groups; 
2) diagnoses remitted for CBT treatments versus comparison 
groups; and 3) symptom improvements for selective-serotoniner-
gic-reuptake-inhibitors (SSRIs) (fluoxetine, fluvoxamine, paroxe-
tine and sertraline) versus placebo. We extracted or calculated odds 
ratios (OR) for diagnostic and/or symptom improvement, then 
calculated Cochran’s Q to evaluate heterogeneity. Publication 
bias was evaluated by inspecting asymmetry of funnel plots and 
performing an Egger’s test. All statistical analyses were conducted 
using the Meta-Analysis Package for R.26 This review was regis-
tered with PROSPERO (registration number CRD42016052643; 
see www. crd. york. ac. uk/ PROSPERO/).
FindingS
Prevention programmes
Eight RCTs met inclusion criteria, evaluating 8 prevention 
programmes: 5 delivered in schools and 3 in other commu-
nity settings.27–36 One programme—Coping and Promoting 
Strength—was evaluated in 2 RCTs while the others were 
evaluated in single RCTs. One RCT also evaluated 2 interven-
tions: Cognitive Bias Modification and a CBT programme. One 
programme was universal while 7 focused on at-risk children, 
Table 1 Randomised controlled trial inclusion criteria*
1 Children ≤18 years of age were the main focus or were clearly reported on separately if part of an adult study.
2 Interventions aimed to prevent or treat anxiety disorders.
a. For prevention, at enrolment/pretest, <50% had a primary anxiety disorder diagnosis.
b. For treatment, at enrolment/pretest, ≥50% had a primary anxiety disorder diagnosis.
3 Clear descriptions were provided of participant characteristics, study settings and interventions.
4 Participants (or clusters) were randomly assigned to intervention and either control (no-intervention) or comparison (minimal intervention) groups at study outset.
5 Outcome measures pertained to anxiety, for example, scales had established reliability and validity or ≥50% of items addressed anxiety symptoms.
6 Anxiety indicators included either 1 diagnostic measure where the diagnostician was blinded or 2 symptom measures evaluated by 2 or more informant sources, for 
example, child, parent or teacher, at least one of whom was blinded.
7 Maximum attrition was 20% at post-test (medication studies) or at follow-up (prevention or psychosocial treatment studies) or authors used intention-to-treat analyses.
8 For prevention and psychosocial treatment studies, postintervention follow-up was 3 months or more.
9 For medication studies, double-blinding and placebo controls were used, and side effects were comprehensively assessed.
10 Statistical significance (using p<0.05) was reported for relevant outcome measures at post-test (medication studies) or at follow-up (prevention and psychosocial 
treatment studies).
11 Interventions were evaluated in high-income countries (by World Bank standards).
12 Studies focused on populations and settings with applicability to most children who may be at risk of or who may have anxiety, rather than specialised subpopulations.
*For inclusion, all criteria had to be met.
Figure 1 Search process
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that is, with temperamental inhibition, anxiety symptoms or a 
parent with an anxiety disorder.
Six programmes used CBT techniques including psychoedu-
cation, relaxation, cognitive restructuring and exposure exer-
cises.28–30 34–36 Four CBT programmes were delivered to groups of 
children in schools, with 2 also providing parent sessions.28 34–36 
The 2 other CBT programmes focused on parents; 1 was deliv-
ered to individual families and 1 trained parents to provide 
CBT to their young children.29 30 The 2 non-CBT programmes 
used computer delivery. Cognitive Bias Modification aimed to 
reduce negative assumptions in noticing and interpreting social 
situations.36 Meanwhile, Mindset taught teens to cope with 
stress by viewing personality traits as being modifiable.33 All 8 
programmes were relatively brief, ranging from 30 min to 5.5 
months.
Three prevention programmes—all using CBT and all focusing 
on at-risk children—significantly reduced anxiety diagnoses 
and/or symptoms. Coping and Promoting Strength was notable 
for reducing anxiety diagnoses across 2 RCTs, with a large 
effect size for the second (OR=8.54).30 31 This included only 
0%–5% of intervention children developing disorders between 
post-test and 9-month follow-up, compared with 30%–31% of 
controls.30–32Coping and Promoting Strength also significantly 
reduced symptoms: on 2 measures with large effect sizes (Cohen’s 
d [d]=0.82 and 1.99) in the first RCT and on 3 measures with 
medium effect sizes (d=0.54–0.74) in the second.30 31 Cool Little 
Kids and Friends also significantly reduced symptoms on one 
measure but did not reduce diagnoses.29 35
Five prevention programmes failed to show benefits pertaining 
to anxiety, including 3 CBT programmes (Aussie Optimism, 
Feelings Club and Generic CBT) and both non-CBT programmes 
(Cognitive Bias Modification and Mindset).27 28 33 34 36 Adverse 
events were only assessed for Feelings Club; none were reported 
by children or parents.34 Table 2 summarises the 8 prevention 
evaluations.
Psychosocial treatments
Fourteen RCTs met inclusion criteria, evaluating 12 psychosocial 
treatments: 1 delivered in homes, 8 in clinics and 3 in schools. 
37–50 w51 Two treatments—Coping Cat and Skills for Academic 
and Social Success (SASS)—were evaluated in 2 RCTs while the 
others were evaluated in single RCTs.42 45 50 w51 As well, 3 RCTs 
compared different formats including individual child versus 
individual family delivery42 and psychologist versus counsellor 
delivery.w51 Most studies included children with a variety of 
anxiety disorders.
Eleven treatments used CBT, delivered to children and 
parents individually and in groups in a variety of settings. The 
only non-CBT treatment, Attention Bias Modification Training 
(ABMT), used computers to teach children to reduce their focus 
on socially threatening situations.41 All treatments were rela-
tively brief, ranging from 3 hours to 6 months.
Table 2 Prevention programme descriptions and evaluation findings
Programme
Sample size
(country)
Ages/grades
(risk factors) Programme elements
Session number and 
duration
Follow-up
period*
Child anxiety outcomes
(diagnostic rates)†
universal programmes—school-based
Aussie Optimism27 28 910
(Australia)
Grade 4
(not applicable)
Child group CBT‡ 10 sessions over 
2.5 months
2.5 years • 1 of 1 symptom
1.5 years • Any AD diagnoses (3% vs 4%)
Targeted programmes—community-based
Cool Little Kids29 545
(Australia)
4 years
(temperamental 
inhibition)
Parent group CBT training 6 sessions over 3 months 9 months • SAD, SP, SpAD + GAD diagnoses (44% 
vs 50%)
↓ 1 of 1 symptom
Coping and Promoting 
Strength I30
40
(USA)
7–12 years
(parent with an anxiety 
disorder)
Family CBT 9–11 sessions over 
5 months
9 months ↓ Any AD diagnoses§ (0% vs 30%)
↓ 2 of 3 symptoms
Coping and Promoting 
Strength II31 32
136
(USA)
6–13 years
(parent with an anxiety 
disorder)
Family CBT 11 sessions over 5 months 9 months ↓ Any AD diagnoses§ (5% vs 31%)
↓ 3 of 4 symptoms
Mindset33 96
(USA)
12–15 years
(anxiety/depressive 
symptoms)
Child individual training 
on trait modifiability via 
computer
1 30-min session 9 months • 2 of 2 symptoms
Targeted programmes—school-based
Feelings Club34 148
(Canada)
Grades 3–6
(anxiety/depressive 
symptoms)
Child group 
CBT + parent group 
education
12 child + 3 parent 
sessions over 3 months
1 year • Any AD diagnoses (7% vs 10% by 
parent report; 8% vs 17% by child report)
• 1 of 1 symptom
Friends35 260
(Australia)
Grade 7
(anxiety symptoms)
Child group 
CBT + parent group 
education
12 child + 1–2 parent 
sessions over 5.5 months
3.75 years • Any AD diagnoses¶ (23% vs 24%)
↓ 1 of 2 symptoms
Generic Cognitive Behavioural 
Therapy
240
(Netherlands)
12–16 years
(anxiety symptoms)
Child group CBT 10 sessions over 
2.5 months
2 years • SAD diagnoses (2% vs 6%)
• 4 of 4 symptoms
Cognitive Bias Modification36 Child individual cognitive 
bias training via 
computer
20 sessions over 
2.5 months
2 years • SAD diagnoses (10% vs 6%)
• 4 of 4 symptoms
• Denotes no significant differences between intervention and comparison group.
↓ Denotes statistically-significant reductions in diagnoses/symptoms favouring intervention over comparison group.
* Follow-up period counted from end of intervention including booster sessions, where applicable.
† Diagnostic rates for intervention versus comparison children.
‡ Programme addressed both anxiety and depression.
§ Included children with AD diagnosis from post-test to final follow-up.
¶ Included children with AD diagnosis at any point in year prior to the final follow-up.
AD, anxiety disorder; CBT, cognitive behavioural therapy; GAD, generalised anxiety disorder; SAD, social anxiety disorder; SP, specific phobia; SpAD, separation anxiety disorder.
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Ten psychosocial treatments—all CBT—significantly reduced 
anxiety diagnoses and/or symptoms by final follow-ups. The 
home-based Strongest Families reduced diagnoses (approx-
imately 25% for intervention children vs 50% for controls) 
with a large effect size (OR=2.51).37 Of the clinic-based treat-
ments, Cool Little Kids Plus Social Skills reduced diagnoses 
(66% vs 100%) and number of disorders per child (d=1.76); 
it also reduced symptoms on 3 measures, with large effect sizes 
(d=0.89–2.11).38 Cool Kids also reduced primary diagnoses (31% 
vs 55%), any anxiety diagnoses (51% vs 70%) and symptoms 
on 3 measures.43 Parent Education Program reduced diagnoses 
(40% vs 69%) and symptoms on 2 measures.39 Timid to Tiger 
reduced primary diagnoses (46% vs 76%) and any anxiety diag-
noses (54% vs 91%), both with large effect sizes (OR=3.68 and 
8.50, respectively), but had no impact on symptoms.40 One-Ses-
sion Treatment reduced specific phobia diagnoses (51% vs 65%) 
as well as symptoms on 1 measure.44 Meanwhile, Coping Cat 
reduced anxiety diagnoses (18% vs 35%) and symptoms on 1 
Table 3 Psychosocial treatment descriptions and evaluation findings
Programme
(diagnoses)
Sample size
(country)
Ages/grades Programme elements
Session number and 
duration
Follow-up
period*
Child anxiety outcomes
(diagnostic rates)†
home-based
Strongest Families
(GAD, SpAD, SAD, SP)37
91
(Canada)
6–12 years Self-directed family CBT with 
coaching
13 sessions over 6.5 months 5.5 months ↓ Any AD diagnoses (25% vs 50%)‡
Clinic-based
Cool Little Kids Plus Social Skills
(SAD, GAD, SpAD, SP)38
72
(Australia)
2–5 years Parent group CBT 
training + child group SST
6 parent + 6 child sessions 
over 2.5 months
3 months ↓ Any AD diagnoses (66% vs 100%)
↓ # of AD diagnoses
↓ 3 of 5 symptoms
Parent Education Program
(SoP, SP, SpAD, GAD)§39
146
(Australia)
3–4 years Parent group CBT training 6 sessions over 2.5 months 3 years ↓ Any AD diagnoses (40% vs 69%)
↓ 2 of 3 symptoms
Timid to Tiger
(SpAD, SAD, SP, PD, GAD)40
74
(England)
2–9 years Parent group CBT training 10 sessions over 2.5 months 1 year ↓ Primary AD diagnoses (46% vs 76%)
↓ Any AD diagnoses (54% vs 91%)
• 3 of 3 symptoms
Attention Bias Modification 
Treatment
(SAD)41
67
(Israel)
6–18 years Child individual attention bias 
training via computer 
8 sessions over 1 month 3 months • 2 of 2 symptoms
Coping Cat Individual 161
(USA)
7–14 years Child individual CBT¶ 16 sessions over 4 months 1 year • Primary AD diagnoses (39% vs 56%)
↓ 1 of 8 symptoms
Coping Cat Family
(GAD, SoP, SpAD)42
Family CBT • Primary AD diagnoses (42% vs 56%)
• 8 of 8 symptoms
Cool Kids
(GAD, SoP, SpAD, PD, SP)43
112
(Australia)
7–16 years Child group 
CBT + parent group CBT 
training
10 sessions over 2.5 months 3 months ↓ Primary AD diagnoses (31% vs 55%)
↓ Any AD diagnoses (51% vs 70%)
↓ 3 of 6 symptoms
One-Session Treatment
(SP)44
196
(Sweden + USA)
7–16 years Child individual CBT 1 session over 3 hours 6 months ↓ SP diagnoses (51% vs 65%)
↓ 1 of 6 symptoms
Coping Cat
(GAD, SpAD, SAD)45
133
(USA)
9–14 years Child individual CBT¶ 14 sessions over unnamed 
period
1 year ↓ Any AD diagnoses (18% vs 35%)
↓ 1 of 3 symptoms
Generic CBT
(SAD)46
73
(USA)
12–17 years Child individual or group CBT 12 sessions over 3 months 6 months • 5 of 5 symptoms
School-based
Friends (with or without parent 
involvement)∗∗
(SAD, GAD, SoP)†† 
47 48
61
(USA)
Grades 2–5 Child group CBT ± 
parent group CBT training
11 child + 9 parent sessions 
over 5 months
2.75 years ↓ 1 of 5 symptoms
3 months • Primary AD diagnoses (14%–25% 
vs 40%)
• New AD diagnoses (15%–29% vs 
29%)
Coping Koala
(SoP, SP, GAD, SpAD)†† 49
128
(Australia)
Grades 3–7 Child group 
CBT + parent group CBT 
training
10 child + 3 parent sessions 
over 2.5 months
2 years ↓ Any AD diagnoses (20% vs 39%)
↓ 2 of 6 symptoms
Skills for Academic and Social 
Success (SASS)
(SAD)50
36
(USA)
Grades 9–11 Child group 
CBT + parent + teacher 
education
20 child + 2 parent/
teacher sessions over 
5 months
4 months ↓ SAD diagnoses (27% vs 93%)
↓ 2 of 5 symptoms
SASS Psychologist-Delivered 138
(USA)
Grades 9–11 Child group 
CBT + parent + teacher 
education
20 child + 2 parent/teacher 
sessions over 5 months
3 months • SAD diagnoses (72% vs 88%)
↓ 4 of 5 symptoms
SASS Counsellor-Delivered
(SAD)w51
↓ SAD diagnoses (61% vs 88%)
↓ 3 of 5 symptoms
↓ Denotes statistically-significant reductions in diagnoses/symptoms favouring treatment over comparison group.
• Denotes no significant differences between treatment and comparison groups.
* Follow-up period counted from end of treatment including booster sessions, where applicable.
† Diagnostic rates for intervention versus comparison.
‡ Rates are approximate.
§ Approximately 93% met criteria for anxiety disorder; remainder had temperamental inhibition.
¶ Parent involvement in 2 sessions including psychoeducation and coaching on responding to anxious behaviours.
** Because there was no difference in outcomes for Friends with and without parent involvement combined results from 2 treatment groups are reported.
†† Approximately 75% met criteria for anxiety disorder; remainder were symptomatic.
AD, anxiety disorder; CBT, cognitive behavioural therapy; GAD, generalised anxiety disorder; PD, panic disorder; SAD, social anxiety disorder; SoP, social phobia; SP, specific phobia; SpAD, 
separation anxiety disorder; SST, social skills training.
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measure (OR=3.29 and 2.56, respectively) in 1 trial.45 In the 
other Coping Cat trial, primary anxiety diagnoses were not 
significantly reduced for either child or family formats; however, 
the child version did reduce symptoms on 1 measure.42
For school-based treatments, Coping Koala reduced diagnoses 
(20% vs 39%) and symptoms on 2 measures.49 SASS (delivered 
by psychologists and psychology graduate students) and Counsel-
lor-Delivered SASS both reduced social anxiety diagnoses (27% 
vs 93% and 61% vs 88% [OR=4.89], respectively, although 
Psychologist-Delivered SASS did not).50–w51 All SASS versions 
also reduced symptoms on 2-to-4 measures, with moderate-to-
large effect sizes for 2 versions (OR=16.21 and d=0.38–0.93 
for Counsellor-Delivered and OR=7.61 and d=0.34–0.83 
for Psychologist-Delivered). In contrast, Friends improved 1 
symptom measure but failed to reduce diagnoses.47 48
The remaining 2 treatments—both clinic-based—showed 
no benefits: Generic CBT and ABMT (the only non-CBT treat-
ment).41 46 Adverse events were assessed for 2 treatments. 
Strongest Families participants reported no adverse events, 
and none were observed for One-Session Treatment partic-
ipants.37 44 Table 3 summarises the 14 psychosocial treatment 
evaluations.
Pharmacological treatments
Eleven RCTs met inclusion criteria, evaluating 7 medications: 
SSRIs (fluoxetine, fluvoxamine, paroxetine and sertraline); a 
tricyclic (imipramine); a selective-noradrenergic-reuptake-in-
hibitor (venlafaxine); and an N-methyl-D-aspartate-partial-ag-
onist (D-cycloserine).w52–w62 Fluoxetine was evaluated in 3 
RCTs while imipramine and sertraline were each evaluated 
in 2.w54–w58 w60–w61 The other medications were evaluated in 
single RCTs.w52 w53 w59 w62 In addition to placebos, fluoxe-
tine was compared with behaviour treatment in 1 RCTw54 
and with CBT in another,w56 while sertraline was compared 
with CBT in 1 RCT.w61 All medications were assessed at post-
test only, except D-cycloserine which was assessed at 1-week 
follow-up.w52 Some studies included children with a variety of 
Table 4 Pharmacological treatment descriptions and evaluation findings
Medication
[daily dose]*
(diagnoses)
Sample size
(country) Ages duration
Child anxiety outcomes 
(diagnostic rates)†
Child
adverse events
D-cycloserine
[50 mg]
(SP)w52
37
(Australia)
6–14 years Single dose ↓ 2 of 2 symptoms‡ Headache 39%; left study due to adverse events 0%
Fluvoxamine
[50–300 mg]
(SoP, SpAD, GAD)w53
128
(USA)
6–17 years 2 months ↓ 2 of 2 symptoms Abdominal discomfort 49%§; headache 43%; left study due to 
adverse events 8%
Fluoxetine I¶
[40 mg]
(SAD)w54
139
(USA)
7–17 years 3 months ↓ SAD diagnoses (79% vs 
97%)
↓ 4 of 8 symptoms
Nausea % NR§; left study due to adverse events 0%
Fluoxetine II
[10–20 mg]
(GAD, SoP, SpAD)w55
74
(USA)
7–17 years 3 months ↓ 1 of 6 symptoms Abdominal pain or nausea 46%§; drowsiness 44%§; headaches 
14%§; left study due to adverse events 14%
Fluoxetine III¶
[10–60 mg]
(SoP, GAD, SpAD)w56
62
(Australia)
11–16 years 6 months • AD diagnoses (68% vs 
77%)
• 4 of 4 symptoms
Left study due to adverse events 5%
Imipramine I
[100–200 mg]
(NR)** w57
42
(USA)
6–14 years 1.5 months ↓ 8 of 8 symptoms Drowsiness 62%; dry mouth 50%§; constipation 31%; dizziness 
25%; left study due to adverse events % NR
Imipramine II
[75–275 mg]
(SpAD)w58
21
(USA)
6–15 years 1.5 months • 29 of 29 symptoms†† Dry mouth 46%; irritability 27%; changes in ECG % NR§; left 
study due to adverse events 0%
Paroxetine
[10–50 mg]
(SAD)w59
322
(USA, South Africa, 
Canada Belgium)
8–17 years 4 months ↓ 6 of 6 symptoms Insomnia 14%§; left study due to adverse events 6%
Sertraline I
[50 mg]
(GAD)w60
22
(USA)
5–17 years 2.25 months ↓ 6 of 7 symptoms Drowsiness 73%; dry mouth 55%; restlessness 55%; leg spasms 
36%; left study due to adverse events 0%
Sertraline II¶
[25–200 mg]
(SpAD, GAD, SoP)w61
488
(USA)
7–17 years 3 months ↓ 2 of 4 symptoms
NR 2 of 4 symptoms
Insomnia 8%; fatigue 6%; sedation 5%; restlessness 4%; fever 
1%‡‡; left study due to adverse events 6%
Venlafaxine
[37.5–225 mg]
(SAD)w62
293
(USA)
8–18 years 4 months ↓ 2 of 2 symptoms Nausea 23%§; anorexia 22%§; weakness or loss of energy 
20%§; sore throat 19%§; weight loss 11%§; dilated pupils 4%§; 
abnormal behaviour 4%§; heart rate increase % NR§; PR interval 
decrease % NR§; pulse rate increase % NR§; blood pressure 
increase % NR§; left study due to adverse events 4%
↓ Denotes statistically-significant reductions in symptoms favouring medication over placebo.
• Denotes medication did not show statistically-significant benefit over placebo.
* Reported doses include widest range that children received at point therapeutic dose achieved; dosing is not equivalent across medications.
† Diagnostic rates for medication versus placebo.
‡ Assessed 1 week after medication was administered.
§ Adverse event(s) experienced by significantly more children on medication than placebo.
¶ Medication was also compared with a psychosocial treatment, as described in text
** All participating children were refusing to attend school or were doing so with marked distressed.
†† One outcome favoured placebo over medication.
‡‡ All adverse events were experienced by significantly more children on sertraline than children participating in cognitive-behavioural therapy.
AD, anxiety disorder; ECG, electrocardiogram; GAD, generalised anxiety disorder; NR, not reported; PD, panic disorder; SAD, social anxiety disorder; SoP, social phobia; SP, specific phobia; 
SpAD, Separation anxiety disorder.
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anxiety disorders,w53 w55 w56 w61 while others focused on single 
disorders.w52 w54 w58–w60 w62
For fluoxetine, 2 RCTs assessed diagnoses and symptoms. In 1 
trial (fluoxetine I; see table 4), the medication significantly reduced 
social anxiety diagnoses (79% for intervention children vs 97% 
for placebo controls) and reduced symptoms on 4 measures.w54 
However, when compared with a 12-week behaviour treatment, 
fluoxetine was less effective at reducing social anxiety diagnoses 
(79% for fluoxetine vs 47% for behaviour treatment) as well as 
at reducing symptoms on 4 measures.w54 In another trial (fluoxe-
tine III), the medication was given with CBT but failed to reduce 
anxiety diagnoses compared with CBT alone or compared with 
CBT plus placebo (68% for fluoxetine plus CBT vs 65% for 
CBT alone vs 77% for CBT plus placebo).w56 Similarly, there 
was no difference among the 3 conditions on symptoms on 4 
measures.w56 A third trial (fluoxetine II) did not assess diagnoses 
but reduced symptoms on 1 measure.w55
For the other 6 medications, RCTs assessed anxiety symp-
toms but not diagnoses. D-cycloserine reduced symptoms 
with medium effect sizes on 2 measures (r=0.35 and 0.37).w52 
Fluvoxamine reduced symptoms on 2 measures.w53 The first 
imipramine RCT showed 8 symptom reductions, with a medium 
effect size for the 1 outcome where this was calculated (Cohen’s 
h=0.73).w57 As well, despite initially refusing to attend school or 
only attending with marked distress, by the end of the trial, 81% 
of intervention children were regularly attending compared with 
only 47% of controls.w57 In contrast, the second imipramine 
RCT found the medication no better than placebo on 28 of 29 
measures and worse on 1.w58 Paroxetine reduced symptoms on 6 
social anxiety measures, with large effect sizes for the 2 outcomes 
where these were calculated (OR=5.44 and 6.05).w59 Sertraline 
also reduced symptoms in 2 RCTs. In the first, it reduced symp-
toms on 6 measures.w60 In the second, it reduced symptoms on 2 
measures compared with placebo with moderate-to-large effect 
sizes (Hedges’ g [g]=0.45; OR=3.9); however, outcomes were 
not significant when compared with CBT.w61 Meanwhile, venla-
faxine reduced symptoms on 2 measures, with moderate effect 
sizes (g=0.46 and number needed to treat=5).w62
Adverse events were common for most medications. These 
included more than 25% of children experiencing: abdom-
inal pain/nausea and drowsiness with fluoxetine; headaches 
with D-cycloserine; abdominal discomfort and headaches with 
fluvoxamine; drowsiness, dry mouth, constipation, irritability 
and dizziness with imipramine; and drowsiness, dry mouth, 
restlessness and leg spasms with sertraline.w52 w53 w55 w57 w58 w60 
Table 4 summarises the 11 medication evaluations, including 
adverse events. (We reported adverse events where at least 25% 
of children were affected or where significantly more children 
on medication versus placebo were affected; however, not all 
studies tested the statistical significance of adverse events.)
risk of bias in included studies
Based on data provided in each RCT, we evaluated 5 risk indica-
tors using the Cochrane risk-of-bias tool.24 25 For most prevention 
studies, bias risks were low, with the exception of performance 
bias. For most psychosocial treatment studies, selection bias 
was unclear, while performance and detection biases were high; 
however, attrition and reporting biases were all low. For most 
medication studies, bias risks were low. Overall risk-of-bias 
profiles favoured medication over psychosocial studies. (Online 
supplementary appendix B gives individual RCT risk-of-bias 
assessments; online supplementary appendix C gives aggregated 
risk-of-bias by intervention category.) We also augmented our 
risk-of-bias assessment to address concerns not covered in the 
Cochrane tool.24 25 Specifically, we identified conflicts-of-inter-
ests for 6 of 11 medication RCTs—with author(s) declaring ties 
to pharmaceutical companies including receiving honouraria, 
owning stock and/or being company employees.w52 w54 w59 w60 w62 
In contrast, conflict-of-interest was reported for only 1 psycho-
social study, with an author declaring the intervention may be 
commercialised.37
Meta-analysis
Beyond identifying specific interventions for preventing and 
treating childhood anxiety to guide policy and practice, we under-
took meta-analyses to determine the common effects of similar 
interventions where there were sufficient RCTs. This included 
CBT prevention programmes, CBT treatment programmes and 
SSRIs. For CBT prevention and treatment programmes, ORs for 
diagnoses prevented or remitted were either extracted or calcu-
lated. Because diagnostic outcomes were not available for most 
SSRI RCTs, we used ORs for symptom improvement.
CBT prevention programmes did not significantly outperform 
comparison conditions for preventing diagnoses (Log OR=0.50; 
95% CI, −0.14  to  1.13). However,  study populations  showed 
significant heterogeneity (Cochran’s Q=16.1, p=0.01). In 
contrast, the CBT treatment programmes significantly outper-
formed comparison conditions for reducing diagnoses (Log 
OR=0.95; 95% CI, 0.69 to 1.21) with acceptable levels of 
heterogeneity (Cochran’s Q=15.5, p=0.16). SSRIs resulted in 
significantly more symptom improvement than placebos at post-
test (Log OR=1.57; 95% CI, 1.09 to 2.06), also with accept-
able levels of heterogeneity (Cochran’s Q=10.56, p=0.06). 
While the Log OR was greater for SSRIs than CBT treatment 
programmes, the latter used a more robust outcome measure—
diagnostic versus symptom improvement. As well, CBT treat-
ments were assessed at follow-ups averaging 10 months, while 
SSRIs were assessed at post-test. (Online supplementary appen-
dices D and E summarise the meta-analyses.)
Regarding publication bias, Egger’s tests showed asymmetry 
in CBT prevention and CBT treatment studies (p<0.01 for 
both) and symmetry in SSRI studies (p=0.21). However, the 
publication bias found for CBT treatment studies had minimal 
impact on our main findings. When we limited the analysis to 
studies with sample sizes greater than 100, asymmetry disap-
peared (p=0.38) and CBT treatment programmes still effec-
tively reduced diagnoses (Log OR=0.92; 95% CI, 0.63 to 1.22). 
(Online supplementary appendix F gives funnel plots assessing 
publication bias.)
ConCluSion And iMPliCATionS
Childhood anxiety disorders come with high costs due, in part, 
to effective prevention and psychosocial treatment interven-
tions not being readily available.2 11 To assist policymakers and 
practitioners in improving this situation, we aimed to identify 
effective interventions—particularly those that were noteworthy 
for reducing childhood anxiety diagnoses. For prevention, the 
CBT programme Coping and Promoting Strength stood out. 
It reduced diagnoses in 6–13-year-olds whose parents had 
anxiety disorders in 2 RCTs. No other prevention programme 
showed comparable success. For psychosocial treatment, 9 CBT 
programmes stood out: Cool Kids, Cool Little Kids Plus Social 
Skills, Coping Cat, Coping Koala, One-Session Treatment, Parent 
Education Program, SASS, Strongest Families and Timid to Tiger. 
These treatments reduced diagnoses using CBT with children 
and families—helping children from early pre-school through 
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the late teen years. For medications, the SSRI fluoxetine success-
fully reduced diagnoses at post-test in 1 RCT with 7–17-year-old 
children. No other medication showed comparable success. 
Most medications, including fluoxetine, caused adverse events.
Based on this review, there is good evidence for making 
targeted prevention investments using CBT programmes such as 
Coping and Promoting Strength. Consequently, this intervention 
should be made readily available for all at-risk children. Preven-
tion has unique potential—to reduce the incidence of anxiety 
disorders early in life, and to reduce the number of children 
going on to develop more severe disorders—and so should be 
prioritised by policymakers, practitioners and researchers, along-
side treatment.w63 Given the relatively limited benefits found for 
many of the prevention programmes, however, more research 
should be conducted to add to the options.
As well, based on this review, the case for CBT for treating 
childhood anxiety disorders is particularly strong. Nine CBT 
treatments showed diagnostic reductions—over a range of child 
ages, delivery formats and settings. Beyond clinical benefits, 
recent cost analyses (including 4 RCTs covered here) found that 
CBT produced net gains of €9500 (US$10,600; 2019 equiva-
lency) per person.w64 Therefore, CBT should be made readily 
available for all children with anxiety disorders, with a focus 
on the 9 successful interventions. That said, future psychoso-
cial research should assess potential adverse events—which were 
seldom evaluated.
Based on this review, there is also evidence that the SSRI fluox-
etine is effective in reducing childhood anxiety diagnoses. There-
fore, when medication is being considered, fluoxetine should 
be considered first. Yet overall, the data suggest that effective 
prevention programming should be offered to all at-risk children 
and CBT should be offered to all children with anxiety disorders 
as first-line treatment, while fluoxetine should be considered for 
children who do not improve with CBT alone. As well, close 
monitoring is needed with any medication so adverse events can 
be managed. Nevertheless, more medication RCTs are needed—
that examine diagnostic outcomes and that are conducted inde-
pendently of pharmaceutical companies.
Our review also has limitations. Our inclusion criteria for 
blinding differed between psychosocial and medication studies, 
which may introduce bias favouring psychosocial studies. We 
took this approach to allow us to include a reasonable number 
of these studies, where double-blinding (and placebo controls) 
are often not feasible. We also noted that in the psychosocial 
studies, more blinded outcomes were statistically significant 
compared with non-blinded (62% vs 19%), suggesting that our 
criteria did not favour these studies. To balance our approach, 
we only required post-test follow-up for medication studies 
while requiring 3-month follow-up for psychosocial studies, 
in turn allowing us to include a reasonable number of medica-
tion studies given that most did not continue beyond post-test. 
Another limitation pertains to the high thresholds we set for 
study inclusion, meaning that we likely excluded many interven-
tions that are being implemented. Yet our approach can serve as 
a model for guiding policy and practice decisions. Namely, when 
RCT evidence of effectiveness is lacking, interventions should 
only be used if there is commitment to evaluating outcomes to 
ensure that children benefit.
On balance, for preventing and treating childhood anxiety, the 
research evidence favours psychosocial interventions in general 
and CBT in particular. To implement this evidence, shifts in policy 
and practice will need to occur. These shifts include allocating 
more funding towards prevention and psychosocial treatments. 
Australia, for example, doubled the proportion of children with 
mental disorders receiving services—from one-third in 1998 to 
two-thirds in 2014—by making significant new public invest-
ments.w65 Other countries could follow suit. It is also crucial 
to reach more children using efficient models such as group or 
online delivery. For example, anxiety prevention and treatment 
programmes can be delivered in schools, with the potential to 
reach many more children than individually-delivered interven-
tions. Shifts in policy and practice regarding psychiatric medica-
tions are also needed, in particular, encouraging the use of CBT 
before considering medications for most children with anxiety.
Making new policy investments can be highly challenging 
given intense competing demands on public budgets. Changing 
practices can also be challenging given longstanding patterns 
of providing care. Yet children’s mental health needs greater 
public investments, and children’s mental health services need to 
evolve as new research evidence becomes available. Given how 
common anxiety disorders are, policymakers and practitioners 
have the opportunity to make a profound difference in the lives 
of many thousands of children. They can do this by investing in 
and delivering effective anxiety interventions across the preven-
tion-through-treatment continuum—so that all children in need 
are reached.
Additional references are provided in online supplementary 
web references.
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